We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
-$368M
Cap. Flow %
-21.39%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Healthcare 17.88%
2 Financials 0.23%
3 Consumer Staples 0.05%
4 Technology 0.03%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TENX icon
76
Tenax Therapeutics
TENX
$419M
$2.96M 0.17%
47
-28
-37% -$1.64M
LJPC
77
CALL
DELISTED
La Jolla Pharmaceutical Company
LJPC
$2.96M 0.17%
1,687
-377
-18% -$7.23K
INDP icon
78
Indaptus Therapeutics
INDP
$231M
$2.93M 0.17%
230
+8
+4% +$93.4K
BIIB icon
79
PUT
Biogen
BIIB
$30.4B
$2.84M 0.17%
100
– –
EIGR
80
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.8M 0.16%
8,018
+325
+4% +$119K
ITCI
81
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.69M 0.16%
1,781
+1,248
+234% +$17.6K
HALO icon
82
CALL
Halozyme
HALO
$9.9B
$2.68M 0.16%
2,708
-2,193
-45% -$24K
EXEL icon
83
CALL
Exelixis
EXEL
$14.2B
$2.66M 0.15%
1,783
-147
-8% -$2.12K
GWPH
84
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.62M 0.15%
234
-39
-14% -$4.69K
CHRS icon
85
PUT
Coherus Oncology
CHRS
$222M
$2.57M 0.15%
+912
New +$25.5K
KYNB
86
CALL
Kyntra Bio
KYNB
$28.2M
$2.54M 0.15%
48
+41
+586% +$20.5K
INSM icon
87
PUT
Insmed
INSM
$22.6B
$2.53M 0.15%
1,913
+666
+53% +$9.09K
PSTV icon
88
Plus Therapeutics
PSTV
$25.9M
$2.49M 0.15%
9
– –
PRTA icon
89
CALL
Prothena Corp
PRTA
$448M
$2.41M 0.14%
490
+165
+51% +$9.1K
TENX icon
90
CALL
Tenax Therapeutics
TENX
$419M
– –
0
– –
TOVX icon
91
Theriva Biologics
TOVX
$9.8M
$2.31M 0.13%
+347
New +$3.56M
AGIO icon
92
CALL
Agios Pharmaceuticals
AGIO
$2.14B
$2.27M 0.13%
545
-3,563
-87% -$187K
PCRX icon
93
CALL
Pacira BioSciences
PCRX
$1.05B
$2.26M 0.13%
700
+391
+127% +$13K
VRTX icon
94
PUT
Vertex Pharmaceuticals
VRTX
$124B
$2.18M 0.13%
296
+36
+14% +$2.93K
ENDP
95
PUT
DELISTED
Endo International plc
ENDP
$2.18M 0.13%
1,323
+227
+21% +$4K
LXRX icon
96
CALL
Lexicon Pharmaceuticals
LXRX
$1.04B
$2.16M 0.13%
1,563
-4,700
-75% -$75.4K
GWPH
97
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.15M 0.12%
192
– –
OPK icon
98
PUT
Opko Health
OPK
$1.23B
$2.12M 0.12%
2,275
+248
+12% +$2.57K
ENDP
99
DELISTED
Endo International plc
ENDP
$2.08M 0.12%
126,139
+66,902
+113% +$1.18M
SIEN
100
PUT
DELISTED
Sientra, Inc.
SIEN
$2.06M 0.12%
+241
New +$20K
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management withdrew a net $368M in Q4 2016, closing 78 positions and reducing 111 holdings. Its most notable exit was Shire pic, an estimated $6.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 9.2% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Eli Lilly worth $15.7M.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.